Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04535102
Title POLA+BR for Relapsed or Refractory DLBCL
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Colorado, Denver
Indications

diffuse large B-cell lymphoma

primary mediastinal B-cell lymphoma

B-cell lymphoma

Therapies

Bendamustine + Polatuzumab vedotin-piiq + Rituximab

Age Groups: adult | senior
Covered Countries


No variant requirements are available.